ClinicalTrials.gg
Status unknownNCT00837863Updated May 7, 2009

Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency

A Phase 2 interventional study of Somatropin and Somatropin in Growth Hormone Deficiency, sponsored by Altus Pharmaceuticals. Status unknown at 11 sites in United States. Open to participants aged 3 Years to 13 Years. Per ClinicalTrials.gov, last updated 2009-05-07.

Sponsored by Altus Pharmaceuticals · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2009), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
3 Years to 13 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Planned enrollment
36th of 60
36 · median 66
Started
2009
with 1 other
Phase 2
6 of 60
1 open now
Registered
27th of 60
by date

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 36th largest by planned enrollment, is one of 2 that started in 2009, is one of 6 in phase 2, and was the 27th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 3 Years to 13 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and effectiveness of ALTU-238 in the treatment of children with growth hormone deficiency who have not yet reached puberty who lack the normal ability to make growth hormone themselves. This study will also test if ALTU-238 works as a weekly treatment.

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
3 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Assent of subject, if applicable, and written of parent or legal guardian
  2. Diagnosis of GHD as defined by a maximum stimulated GH \< 7 ng/mL (μg/L) on two stimulation tests (using any two distinct agents from the following list: arginine, L-dopa, clonidine, insulin, or glucagon); if two documented historical tests are not available,test(s) must be performed during Screening period
  3. Available results from one or more historical CT or MRI scans of the head obtained at or following the diagnosis of GHD
  4. Chronologic age at Screening of 3 to 13 years (inclusive) for boys and 3 to 12 years(inclusive) for girls
  5. Bone age at Screening of ≤ 11 years for boys and ≤ 10 years for girls
  6. Pre-pubertal at Screening (Tanner stage 1 for both breast/genitalia and pubic hair
  7. For subjects with idiopathic GHD, a Screening height SDS ≤ -2.0 (standardized for chronologic age and sex) there is no height SDS requirement if the subject has organic GHD (as defined by a CNS lesion or insult on a historical CT or MRI scan)
  8. Pre-treatment annualized height velocity ≤ median (50th percentile) for chronologic age and sex (based on values for delayed maturers provided in Appendix 4), utilizing Screening height and height obtained 52 ± 13 weeks (i.e. 39 to 65 weeks) prior to Screening
  9. Screening IGF-1 SDS for chronologic age and sex \< -1
  10. If on thyroid hormone replacement therapy, the dose must be stable for at least 6 weeks prior to Screening and the free thyroxine level (T4), TSH, and cortisol must be within the normal range at the Screening visit

Exclusion criteria

Exclusion Criteria:

  1. History of any prior rhGH, rhIGF-1, or sex treatment
  2. History of treatment with any medications that may affect growth
  3. Evidence of active intracranial neoplasm per recent serial CT or MRI scans of the head or other criteria
  4. Surgery/chemotherapy/radiation therapy for intracranial neoplasm within the prior 52 weeks
  5. Any history of non-intracranial neoplasm
  6. History of or active benign intracranial hypertension
  7. High-dose chronic systemic corticosteroid treatment (oral or injected) within prior 13 weeks
  8. Acute or severe illness within prior 26 weeks
  9. History of diabetes mellitus, anorexia nervosa, cystic fibrosis, chronic severe kidney or liver disease, chronic infectious disease, inborn errors of metabolism, chromosomal disorders, intrauterine growth retardation, or other childhood disease associated with growth failure
  10. History of congenital syndromes associated with abnormal growth, including Turner syndrome, Noonan syndrome, Prader-Willi syndrome, etc.
  11. History of severe associated pathology affecting growth, including malnutrition,malabsorption, or bone dysplasia
  12. History of disease
  13. Serum or AST ≥ 1.5X
  14. Participation in another clinical trial or treatment with any agent (drug or biologic) within 30 days prior to Baseline if the half-life of the agent is known to be ≤ 6 days or within 6 weeks prior to Baseline if the half-life is > 6 days or not known
  15. History of any allergic or abnormal reaction to any of the components of the study drugs
  16. Any previous or ongoing illness, PE findings, or laboratory abnormality that, in the opinion of the Investigator or the Medical Monitor, could prevent the subject from completing the protocol-specified requirements successfully
  17. Poor likelihood, in the Investigator's opinion, that the subject will comply with protocol requirements (e.g., uncooperative attitude, inability to return for follow-up visits, history of medical noncompliance) and/or poor likelihood of completing the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    1

    ALTU-238

    Drug: Somatropin

  • Experimental
    2

    ALTU-238

    Drug: Somatropin

  • Experimental
    3

    ALTU-238

    Drug: Somatropin

  • Active comparator
    4

    Nutropin AQ

    Drug: Somatropin

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change in annualized height velocity from pre-treatment to the first 26 weeks of treatment

    Time frame: 26 Weeks

07

Study locations

11 of 11 sites recruiting
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
    Recruiting
    • Dr Stephen Kemp · Contact
    • Dr Stephen Kemp · Principal investigator
  • Nemours Children's Clinic
    Orlando, Florida 32806, United States
    Recruiting
    • Dr. Jorge Daaboul · Contact407-650-7210
    • Dr. Jorge Daaboul · Principal investigator
  • Baystate Medical Centre
    Springfield, Massachusetts 01199, United States
    Recruiting
    • Dr Edward Reiter · Contact413-794-5060
    • Dr Edward Reiter · Principal investigator
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01655, United States
    Recruiting
    • Dr. Leslie Soyka · Contact508-856-6289
    • Dr. Leslie Soyka · Principal investigator
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
    Recruiting
    • Dr. Finen Ugrasbul · Contact816-234-3973
    • Dr. Finen Ugrasbul · Principal investigator
  • Morristown Memorial Hospital
    Morristown, New Jersey 07962, United States
    Recruiting
    • Dr. Lawrence Silverman · Contact973-971-6340
    • Dr. Lawrence Silverman · Principal investigator
  • Schneider Children's Hospital
    New Hyde Park, New York 11040, United States
    Recruiting
    • Dr. Phyllis Speiser · Contact718-470-3290
    • Dr. Phyllis Speiser · Principal investigator
  • Children's Hospital Medical Centre
    Cincinnati, Ohio 45229, United States
    Recruiting
    • Dr Susan Rose · Contact513-636-4744
    • Dr Susan Rose · Principal investigator
  • Cook Children's Hospital
    Ft. Worth, Texas 76104, United States
    Recruiting
    • Dr. Paul Thornton · Contact682-885-7960
    • Dr. Paul Thornton · Principal investigator
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
    Recruiting
    • Dr Patricia Fetchner · Contact
    • Dr Patricia Fetchner · Principal investigator
  • Swedish Medical Center
    Seattle, Washington 98122, United States
    Recruiting
    • Dr. Gad Kletter · Contact206-215-2700
    • Dr. Gad Kletter · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009 and a primary completion of Sep 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2009
First posted
Feb 5, 2009
Start
Mar 2009
Primary completionEst.
Sep 2010
Last update
May 7, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00837863
Lead sponsor
Altus Pharmaceuticals
First posted
Feb 5, 2009
Start date
Mar 2009
Primary completion
Sep 2010 (estimated)
Last update
May 7, 2009

Study contacts

Dr. Kenneth Attie, Medical Monitor
Contact
kattie@altus.com
781-373-6481

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion